Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction

Circulation

Volumn 125, Issue 10, 2012, Pages 1256-1265

  Byrne, Conor J ^a   McCafferty, Kieran ^a   Kieswich, Julius ^a   Harwood, Steven ^a   Andrikopoulos, Petros ^a   Raftery, Martin ^a   Thiemermann, Christoph ^a   Yaqoob, Muhammad M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ischemia; Ischemic postconditioning; Ischemic preconditioning; Myocardial infarction; Renal insufficiency

Indexed keywords

CREATININE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; STAT3 PROTEIN; TROPONIN I;

ACUTE CORONARY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; HEMATOCRIT; ISCHEMIC POSTCONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REMOTE ISCHEMIC PRECONDITIONING; REPERFUSION INJURY; SIGNAL TRANSDUCTION; THERAPY EFFECT; UPREGULATION; UREMIA; WESTERN BLOTTING;

ACUTE CORONARY SYNDROME; ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC; REPERFUSION INJURY; UREMIA;

EID: 84858446857     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.055392     Document Type: Article

References (48)

1. Ansell D, Roderick P, Steenkamp R, Tomson C R V. UK Renal Registry Annual Report. Bristol, UK: UK Renal Registry; 2009.
2. McDonald S, Excell L, Livingston B. ANZDATA Registry Report. Adelaide, South Australia: ANZDATA Registry; 2009.
3. National Institute of Diabetes and Digestive and Kidney Diseases. U. S. Renal Data System Annual Data Report. Ann Arbor, MI: National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
4. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137:563-570.
5. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry. Circulation. 2010;121:357-365.
6. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799-805. (Pubitemid 28447453)
7. Medi C, Montalescot G, Budaj A, Fox K A A, Lopez-Sendon J, Fitz Gerald G, Brieger DB. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv. 2009;2:26-33.
8. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120:851-858.
9. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377-1384. (Pubitemid 44427424)
10. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70:2021-2030. (Pubitemid 44863392)
11. Dragu R, Behar S, Sandach A, Boyko V, Kapeliovich M, Rispler S, Hammerman H. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction? Am J Cardiol. 2006;97:1142-1145.
12. Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, O'Rourke RA, Boden WE, Weintraub WS. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104:1647-1653.
13. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769-2775. (Pubitemid 37498979)
14. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, Moliterno DJ, Nassif D, Lopez JJ, Saucedo JF. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009;2:37-45.
15. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation. 2007;116:1465-1472. (Pubitemid 47480637)
16. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136. (Pubitemid 17174962)
17. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87:893-899. (Pubitemid 23070821)
18. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579-H588. (Pubitemid 36885888)
19. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54:2360-2364. (Pubitemid 41134263)
20. Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM. Preconditioning the diabetic human myocardium. J Cell Mol Med. 2009;14:1740-1746.
21. Przyklenk K, Maynard M, Greiner D, Whittaker P. Restoration of normoglycemia re-establishes the infarct-sparing effect of postconditioning in diabetic mice [abstract 1905]. Circulation. 2008;118(suppl):S402-S403.
22. Abete P, Ferrara N, Cioppa A, Ferrara P, Bianco S, Calabrese C, Cacciatore F, Longobardi G, Rengo F. Preconditioning does not prevent postischemic dysfunction in aging heart. J Am Coll Cardiol. 1996;27:1777-1786. (Pubitemid 26198034)
23. Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol. 2008;51:1393-1398. (Pubitemid 351443077)
24. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res. 2008;102:131-135.
25. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest. 1993;92:2934-2940. (Pubitemid 24006564)
26. Savage T, Tribe RM, Yaqoob MM. Flow induces dilatation in the femoral artery of uraemic rats but constriction in control rats. Nephrol Dial Transplant. 2001;16:1156-1162. (Pubitemid 32547369)
27. New DI, Chesser AM, Thuraisingham RC, Yaqoob MM. Structural remodeling of resistance arteries in uremic hypertension. Kidney Int. 2004;65:1818-1825. (Pubitemid 38591031)
28. Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal model of adenineinduced chronic renal failure in rats. Nephron. 1986;44:230-234. (Pubitemid 16002549)
29. Wayman NS, McDonald MC, Chatterjee PK, Thiemermann C. Models of coronary artery occlusion and reperfusion for the discovery of novel anti-ischemic and anti-inflammatory drugs for the heart. Methods Mol Biol. 2003;225:199-208.
30. Andrikopoulos P, Fraser SP, Patterson L, Ahmad Z, Burcu H, Ottaviani D, Diss JK, Box C, Eccles SA, Djamgoz MB. Angiogenic functions of voltage-gated Na+ channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling. J Biol Chem. 2011;286:16846-16860.
31. Miller L. Analyzing gels and Western blots with ImageJ. http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blotswith- image-j/. Accessed September 29, 2011.
32. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol. 2004;15:1530-1536. (Pubitemid 38679677)
33. Tani M, Honma Y, Hasegawa H, Tamaki K. Direct activation of mitochondrial K (ATP) channels mimics preconditioning but protein kinase C activation is less effective in middle-aged rat hearts. Cardiovasc Res. 2001;49:56-68.
34. Zhao JL, Yang YJ, You SJ, Cui CJ, Gao RL. Different effects of postconditioning on myocardial no-reflow in the normal and hypercholesterolemic mini-swines. Microvasc Res. 2007;73:137-142.
35. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther. 2006;316:154-161. (Pubitemid 41832592)
36. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347-354. (Pubitemid 26075843)
37. Michea L, Villagran A, Urzua A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension. 2008;52:295-300.
38. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018-1022.
39. Gritsopoulos G, Iliodromitis EK, Zoga A, Farmakis D, Demerouti E, Papalois A, Paraskevaidis IA, Kremastinos DT. Remote postconditioning is more potent than classic postconditioning in reducing the infarct size in anesthetized rabbits. Cardiovasc Drugs Ther. 2009;23:193-198.
40. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12:217-234. (Pubitemid 350176695)
41. Lecour S. Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol. 2009;47:32-40.
42. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A. 2001;98:9050-9055. (Pubitemid 32743867)
43. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating RISK: a role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol. 2008;295:H1649-H1656.
44. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation. 2005;112:2143-2148. (Pubitemid 41475808)
45. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech. 2010;3:35-38.
46. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol. 2008;103:501-513.
47. Bøtker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727-734.
48. Sörensson P, Saleh N, Bouvier F, Böhm F, Settergren M, Caidahl K, Tornvall P, Arheden H, Rydén L, Pernow J. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart. 2010;96:1710-1715.